JP5558353B2 - Lcksh2ドメイン結合の小分子阻害剤 - Google Patents
Lcksh2ドメイン結合の小分子阻害剤 Download PDFInfo
- Publication number
- JP5558353B2 JP5558353B2 JP2010521226A JP2010521226A JP5558353B2 JP 5558353 B2 JP5558353 B2 JP 5558353B2 JP 2010521226 A JP2010521226 A JP 2010521226A JP 2010521226 A JP2010521226 A JP 2010521226A JP 5558353 B2 JP5558353 B2 JP 5558353B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- therapeutic agent
- disease
- autoimmune
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本出願は、2007年8月17日出願の米国仮特許出願第60/956,471号の優先権を主張し、その内容全体を本願に引用して具体的に援用する。
本発明は、国立衛生研究所からの契約番号第CA095200号の下に米国政府の支援で成し遂げた。米国政府は、本発明に特定の権利を有する。
CD3ζ鎖pY−ITAMとのLck SH2ドメイン会合を遮断するSMILSの同定
混合リンパ球反応の阻害
細胞毒性試験
膝窩リンパ節局所同種応答の阻害
ラットにおけるMtb誘発性RAのSMILSによる阻害
生体臓器に対するSMILSの効果
Claims (15)
- 以下の化合物72、87、および241
及び
からなる群より選択される化合物の使用であって、免疫応答を調節するための自己免疫疾患の治療薬の製造のための使用。 - 前記免疫応答が抑制される、請求項1記載の使用。
- 前記化合物が、患者の体重に対して0.01mg/kg〜10mg/kgである、請求項1記載の使用。
- 自己免疫疾患の治療のための医薬組成物であって、
以下の化合物72、87、および241
及び
からなる群より選択される化合物を含み、Lckキナーゼの活性を調節する、医薬組成物。 - 前記調節がITAMへの結合の阻害を含む、請求項4記載の医薬組成物。
- 前記調節がキナーゼ活性を阻害することを含む、請求項4記載の医薬組成物。
- 前記化合物が、患者の体重に対して0.01mg/kg〜10mg/kgの量である、請求項4記載の医薬組成物。
- 以下の化合物72、87、および241
及び
からなる群より選択される化合物を含む、自己免疫疾患治療剤。 - 前記自己免疫疾患が関節リウマチである、請求項8記載の自己免疫疾患治療剤。
- 前記自己免疫疾患が、糸球体腎炎、橋本甲状腺炎、多発硬化症、T細胞白血病、全身性エリテマトーデス、重症筋無力症、自己免疫性溶血性貧血、自己免疫性血小板減少性紫斑病、1型糖尿病、クローン病、グレーブス病、およびセリアック病からなる群より選択される、請求項8記載の自己免疫疾患治療剤。
- 前記化合物が、患者の体重に対して0.01mg/kg〜10mg/kgである、請求項8記載の自己免疫疾患治療剤。
- 前記化合物が、患者におけるT細胞の活性化を阻害する、請求項8記載の自己免疫疾患治療剤。
- 前記T細胞が患者の外で接触させられる、請求項12記載の自己免疫疾患治療剤。
- 前記化合物が、関節の腫脹を抑制する、請求項8に記載の自己免疫疾患治療剤。
- 前記自己免疫疾患が、関節リウマチである、請求項8に記載の自己免疫疾患治療剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95647107P | 2007-08-17 | 2007-08-17 | |
US60/956,471 | 2007-08-17 | ||
PCT/US2008/073498 WO2009026239A1 (en) | 2007-08-17 | 2008-08-18 | Small molecule inhibitors of lck sh2 domain binding |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010536795A JP2010536795A (ja) | 2010-12-02 |
JP5558353B2 true JP5558353B2 (ja) | 2014-07-23 |
Family
ID=40378572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010521226A Expired - Fee Related JP5558353B2 (ja) | 2007-08-17 | 2008-08-18 | Lcksh2ドメイン結合の小分子阻害剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8476273B2 (ja) |
EP (1) | EP2184988B1 (ja) |
JP (1) | JP5558353B2 (ja) |
CA (1) | CA2696473A1 (ja) |
WO (1) | WO2009026239A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2616086T3 (es) * | 2009-08-17 | 2017-06-09 | A & G Pharmaceutical, Inc. | Materiales y procedimientos para el desarrollo de un estado de no respuesta inmune específica de antígeno |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003297904A1 (en) * | 2003-12-12 | 2005-07-14 | University Of Maryland, Baltimore | Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain |
JP5007304B2 (ja) * | 2005-06-22 | 2012-08-22 | プレキシコン,インコーポレーテッド | キナーゼ調節のための化合物および方法,およびその適応症 |
-
2008
- 2008-08-18 EP EP08798116.3A patent/EP2184988B1/en not_active Not-in-force
- 2008-08-18 WO PCT/US2008/073498 patent/WO2009026239A1/en active Application Filing
- 2008-08-18 JP JP2010521226A patent/JP5558353B2/ja not_active Expired - Fee Related
- 2008-08-18 CA CA2696473A patent/CA2696473A1/en not_active Abandoned
- 2008-08-18 US US12/674,685 patent/US8476273B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2009026239A1 (en) | 2009-02-26 |
US8476273B2 (en) | 2013-07-02 |
CA2696473A1 (en) | 2009-02-26 |
JP2010536795A (ja) | 2010-12-02 |
EP2184988B1 (en) | 2014-12-17 |
US20110183984A1 (en) | 2011-07-28 |
EP2184988A4 (en) | 2010-12-29 |
EP2184988A1 (en) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
De Clercq | Novel compounds in preclinical/early clinical development for the treatment of HIV infections | |
KR101178318B1 (ko) | 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법 | |
EP3884935B1 (en) | Compounds and methods for inhibiting phosphate transport | |
US20060135415A1 (en) | Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier | |
WO2009045397A1 (en) | Methods for treating polycystic kidney desease (pkd) or other cyst forming diseases | |
JP5681226B2 (ja) | メチルフェニデート誘導体を含む治療剤 | |
KR102588548B1 (ko) | 자가면역질환 및 염증성질환 펩타이드 치료제 | |
CN102686222A (zh) | 包含mgbg的口服递送药物以及治疗疾病的方法 | |
US11274132B2 (en) | Combined preparations of PKM2 modulators and HMGB1 | |
US20040010045A1 (en) | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer | |
JP5558353B2 (ja) | Lcksh2ドメイン結合の小分子阻害剤 | |
EP3880207B1 (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
US20230277523A1 (en) | Methods for inhibiting phosphate transport | |
US11345729B2 (en) | Recombinant fusion protein of BAF57 and uses thereof | |
WO2003092616A2 (en) | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer | |
JP2014532636A (ja) | ウイルス感染の処置のためのヌクレオシドアナログおよび該処置に対する感受性を評価するための方法 | |
US20070072932A1 (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
KR102259058B1 (ko) | Herpud1 억제제를 유효성분으로 포함하는 결핵의 예방 또는 치료용 약학 조성물 | |
WO2018136933A1 (en) | Inhibition of stromal interaction molecule 1 (stim1) as a co-treatment for adult onset polycystic kidney disease (adpkd) | |
RU2818453C2 (ru) | Комбинация ингибитора mcl-1 и мидостаурина, ее применения и фармацевтические композиции | |
JP2006517227A (ja) | 免疫細胞活性を調節する組成物およびその検出方法 | |
KR101627045B1 (ko) | 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물 | |
Catarsi et al. | PS1447 ANALYSIS OF UPR-RELATED GENE EXPRESSION IN CD34+ CELLS FROM PATIENTS WITH PRIMARY MYELOFIBROSIS REVEALS DOWNREGULATION OF UPR GENES AND REDUCTION OF APOPTOSIS | |
AU2004243491B2 (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
Cris Constantinescu et al. | Treatment Strategies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130701 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140313 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140409 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140604 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5558353 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |